Cover Image
Market Research Report

Competitor Analysis: Biosimilar & Biosuperior Therapeutic Antibodies - 2016 Update

Published by La Merie Publishing Product code 327820
Published Content info 462 Pages
Immediate Delivery Available
Price
Back to Top
Competitor Analysis: Biosimilar & Biosuperior Therapeutic Antibodies - 2016 Update
Published: May 25, 2016 Content info: 462 Pages
Description

This Competitive Intelligence report about ‘Biosimilar & Biosuperior Therapeutic Antibodies’ updates the competitive landscape of biosimilar therapeutic antibodies as of May 2016. The report evaluates the the first wave of biosimilar recombinant monoclonal antibodies in comparison with the corresponding originator antibodies and biosuperior antibodies against the same target. The report also describes the next wave of potential biosimilar versions of therapeutic antibodies loosing patent protection in the time frame of 2019 - 2023. The report specifically lists for each target the branded products with their 2015 sales and up-side indications in development, as well as biosuperior and biosimilar antibody drug candidates in development.

The report includes a compilation of marketed, approved and currently active projects in research and development of biosimilar and biosuperior therapeutic antibodies against commercially and clinically validated targets relevant for the first wave of biosimilar antibodies (VEGF, TNF, Her2, CD20, EGF-R). Relevant first wave originator therapeutic antibodies are Humira, Enbrel, Remicade, Avastin, Lucentis, Eylea, Herceptin, Rituxan / MabThera and Erbitux. Second generation therapeutic antibodies against these targets such as Symponi, Cimzia, Cyramza, Perjeta, Arrzera are also subject of biosimilar activities.

The report also addresses the slowly emerging second wave of biosimilar antibody activities against originator therapeutic antibodies such as abatacept, alemtuzumab, denosumab, eculizumab, omalizumab, pavilizumab, tocilizumab, and ustekinumab.

Competitor projects are listed in a tabular format providing information on:

  • Drug Codes,
  • Target / Mechanism of Action,
  • Class of Compound,
  • Company,
  • Product Category,
  • Indication,
  • R&D Stage and
  • additional comments with a hyperlink leading to the source of information.

SAMPLE

Blockbuster Therapeutic Antibodies in 2015
(by generic name)

Table of Contents
Product Code: LMCA0114

Table of Contents

A) 2015 Sales of Therapeutic Antibodies

  • Overview: 2015 Biologics Sales per Class of Products
  • Overview: 2015 Therapeutic Antibody Sales per Class of Products
  • Blockbuster Therapeutic Antibodies in 2015
  • Anti-TNF Antibody Sales in 2015
  • Cancer Antibody Sales in 2015
  • Other Anti-Inflammatory Antibody Sales in 2015
  • Ophthalmic Antibody Sales in 2015
  • Cardiometabolic & Anti-Infective Antibody Sales in 2015

B) Biosimilar and Biosuperior Anti-TNF Antibodies - 2016 Update

1. Originator Anti-TNF Antibodies

  • Approved and Marketed Indications of anti-TNF Antibodies in Regulated Markets
  • 2015 Sales of Anti-TNF Antibodies
  • Sales of Anti-TNF Antibodies in Q1/2016
  • Humira Pipeline of Recently Approved Indications & Upside Developments
  • Remicade Pipeline of Recent Approvals & Upside Indications
  • Enbrel Pipeline of Upside Indications
  • Simponi Pipeline of Recent Approvals & Upside Indications
  • Cimzia Pipeline of Recent Approvals & Upside Indications
  • Defense Strategies against Biosimilar Anti-TNF Antibodies

2. Biosuperior Anti-TNF Antibodies

  • Non-Antibody Anti-TNF Biosuperiors
  • Anti-TNF Biosuperior Antibodies

3. Biosimimilar Anti-TNF Antibodies

  • Humira Biosimilar Antibodies:
    • Developments in Regulated Markets
    • Developments in Less Regulated Markets
  • Enbrel Biosimilar Antibodies:
    • Developments in Regulated Markets
    • Developments in Less Regulated Markets
  • Remicade Biosimilar Antibodies:
    • Developments in Regulated Markets
    • Developments in Less Regulated Market
  • Simponi & Cimzia Biosimilar Antibodies

C) Biosimilar and Biosuperior Anti-VEGF/-R Antibodies - 2016 Update

1) Marketed Anti-VEGF/R Products in Oncology

  • Avastin, Zaltrap & Cyramza Sales 2008 - 2015
  • Avastin Sales and Indication Portfolio
  • Zaltrap Sales and Indication Portfolio
  • Cyramza Sales and Indication Portfolio

2) Anti-VEGF Biosuperiors of Avastin and Zaltrap

  • Anti-VEGF Biosuperior Pipeline in Oncology
  • Bispecific Anti-VEGF Pipeline in Oncology

3) Anti-VEGF-R Biosuperiors of Cyramza

  • Anti-VEGF-R Biosuperior Pipeline in Oncology
  • Bispecific Anti-VEGF-R Pipeline in Oncology

4) Avastin & Cyramza Biosimilar Pipeline in Oncology

5) Marketed Anti-VEGF Products in Ophthalmology

  • Lucentis & Eylea Sales 2008 - 2015
  • Lucentis Sales & Indication Portfolio
  • Eylea Sales & Indication Portfolio

6) Anti-VEGF Biosuperiors of Lucentis and Eylea

  • Biosuperior Anti-VEGF in Ophthalmology
  • Biosuperior Bispecific Anti-VEGF and Anti-VEGF Combinations in Ophthalmology

7) Other Anti-VEGF Molecules in Ophthalmology

8) Lucentis Biosimilars in Ophthalmology

9) Eylea Biosimilars in Ophthalmology

10) Off-Label Use of Anti-VEGF in Ophthalmology

D) Biosimilar and Biosuperior Anti-Her2 Antibodies - 2016 Update

1. 2015 Anti-Her2 Antibody Sales

2. Originator Anti-Her2 Antibodies

  • Herceptin Approved Indications & Pipeline
  • Perjeta Approved Indications & Pipeline
  • Kadcyla Approved Indications & Pipeline

3. Biosuperior Anti-Her2 Antibodies

  • 3rd Generation Anti-Her2 Antibodies
  • Bispecific Anti-Her2 Antibodies
  • Anti-Her2 Antibody-Drug Conjugates, Immunotoxins, Immunocytokines & Radiopharmaceuticals

4. Biosimilar Anti-Her2 Antibodies

  • Herceptin Biosimilar Antibodies
    • Developments in Regulated Markets
    • Development in Less Regulated Markets

5. Perjeta Biosimilar Antibodies

E) Biosimilar and Biosuperior Anti-CD20 Antibodies - 2016 Update

1. 2015 Sales of Anti-CD20 Antibodies

2. Originator Anti-CD20 Antibodies

  • Rituxan / MabThera Approved Indications & Pipeline
  • Gazyva Approved Indications & Pipeline
  • Arzerra Approved Indications and R&D Pipeline
  • Zevalin Approved Indications

3. Biosuperior Anti-CD20 Antibodies

  • 3rd Generation Anti-CD20 Antibodies
  • Bispecific Anti-CD20 Antibodies
  • Anti-CD20 Antibody-Drug Conjugates, Immunotoxins & Immunocytokines

4. Biosimilar Anti-CD20 Antibodies

  • Rituxan/MabThera Biosimilar Antibodies:
    • Developments in Regulated Markets
    • Developments in Less Regulated Markets

5. Arzerra Biosimilar Antibodies

F) Biosimilar and Biosuperior Anti-EGF-R Antibodies - 2016 Update

1. Sales of Anti-EGF-R Antibodies

2. Originator Anti-EGF-R Antibodies

  • Erbitux Approved Indications & Pipeline
  • Vectibix Approved Indications & Pipeline
  • Nimotuzumab Approved Indications & Pipeline
  • Portrazza Approved Indications & Pipeline

3. Biosuperior Anti-EGF-R Antibodies

  • 3rd Generation Anti-EGF-R Antibodies
  • Bispecific Anti-EGF-R Antibodies
  • Anti-EGF-R Antibody Drug Conjugates

4. Biosimilar Anti-EGF-R Antibodies

  • Erbitux Biosimilar Antibodies:
    • Developments in Regulated Markets
    • Developments in Less Regulated Markets

G) Next Wave of Biosimilar Antibodies - 2016 Update

  • Abatacept Biosimilar Antibodies
  • Aletuzumab Biosimilar Antibodies
  • Denosumab Biosimilar Antibodies
  • Eculizumab Biosimilar Antibodies
  • Omalizumab Biosimilar Antibodies
  • Palivizumab Biosimilar Antibodies
  • Tocilizumab Biosimilar Antibodies
  • Ustekinumab Biosimilar Antibodies
  • Biosimilars of Immune Checkpoint Inhibitor Antibodies

H) Corporate Biosimilar & Biosuperior Therapeutic Antibody Pipelines

Compenies mentioned:

  • 3SBio (Shenyang Sunshine Pharmaceutical Co)
  • AbbVie
  • AbClon
  • Ablynx
  • AET Biotech
  • Affibody
  • Affilogic
  • Affimed Therapeutics
  • Affitech
  • Allergan
  • Alopexx Oncology
  • Alteogen
  • Alvogen
  • Ambrx
  • Amega Biotech
  • Amgen
  • AngioChem
  • Apexigen
  • Aprogen
  • Archemix
  • AREVA Med
  • Aryogen
  • Ascendis Pharma
  • AstraZeneca (MedImmune)
  • Avaxia Biologics
  • AVEO Pharmaceuticals
  • Axxo
  • Baliopharm
  • Baxalta
  • Bayer
  • Binex
  • Bio Farma
  • biOasis Technologies
  • Biocad
  • BioCND
  • Biocon
  • Bioeq
  • Biogen
  • Bionovis
  • BioXpress Therapeutics
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Celgene
  • Celltrion
  • Centrose
  • Ceres Oncology
  • Chengdu Kanghong Biotech Co.
  • CIMAB
  • Cipla
  • Clearside Biomedical
  • Coherus Biosciences
  • Complix
  • Cristalia
  • Curaxys
  • CytomX Therapeutics
  • Daewoong Pharmaceutical Co
  • Daiichi Sankyo
  • Delenex Therapeutics
  • Dermira
  • Dong-A ST
  • Dr Reddy's Laboratories
  • Eddingpharma
  • Eisai
  • Eli Lilly
  • EnGenlC
  • Epirus Biopharmaceuticals
  • Esperance Pharmaceuticals
  • Exicure
  • Ferring Pharmaceuticals
  • ForSight VISION4
  • Fosun Pharma
  • Fujifilm Kyowa Kirin Biologics
  • Gansu Duyiwei Biological Pharmaceutical Co
  • Gedeon Richter
  • Gene Techno Science (GTS)
  • GenIlac
  • Genor Biopharma
  • Glenmark Pharmaceuticals
  • Gliknik
  • Glycotope
  • Green Cross
  • Halozyme
  • HanAll Pharmaceuticals
  • Hanwha Chemical Biologics Business
  • Harvest Moon Pharmaceuticals
  • Helvetic BioPharma
  • Hetero Group
  • Hyprocell
  • IBC Generium
  • Ildong Pharmaceutical
  • Immune Pharmaceuticals
  • ImmuneXcite
  • Immunomedics
  • Innogene Kalbiotech
  • Innokeys
  • Innovent Biologics
  • Intas Pharmaceuticals
  • Janssen (Johnson & Johnson)
  • JHL Biotech
  • Jiangsu Simcere Pharmaceutical
  • Jiangsu T-mab Biopharma
  • Kissei Pharmaceutical
  • Kyowa Hakko Kirin
  • LegoChem
  • LG Life Sciences
  • Libbs Farmaceutica
  • Mabion
  • MabTech
  • MabXience
  • MacroGenics
  • Meiji Seika
  • Merck (MSD)
  • Merck Biopharma & HealthCare Biosimilars
  • Merrimack Pharmaceuticals
  • Mersana Therapeutics
  • Merus
  • Mitsubishi Tanabe Pharma
  • Mochida
  • Molecular Partners
  • Molecular Templates
  • Momenta Pharmaceuticals
  • Mundipharm
  • Mycenax Biotech
  • Mylan Pharmaceuticals
  • Nanogen Biopharmaceutical Co
  • Natco Pharma
  • Neurotech
  • Nichi-iko Pharmaceutical
  • Nippon Kayaku
  • Novartis (& Sandoz/Alcon)
  • Oncobiologics
  • OncoMed Pharmaceuticals
  • Ophthea
  • Ophthotech
  • Orygen Biotecnologia
  • PanOptica
  • Paras Biopharmaceuticals
  • Pfenex
  • Pfizer (& Hospira)
  • PharmAbcine
  • Pharmamar
  • Pharmapraxis
  • Pieris Pharmaceuticals
  • PlantForm
  • Polpharma Group
  • Probiomed
  • Protalix Biotherapeutics
  • Ranbaxy
  • Regeneron Pharmaceuticals
  • Reliance Life Sciences
  • Roche
  • Samsung Bioepis (JV of Samsung and Biogen)
  • Sanofi
  • Senju Pharmaceutical
  • Shanghai Biomabs Pharmaceutical
  • Shanghai Celgen BioPharmaceutical Co
  • Shanghai Citi Pacific (CO) Guojian Pharmaceutical Co (CPGP)
  • Shanghai Fudan-Zhangjiang BioPharmaceuticals
  • Shanghai Henlius Biotech
  • Shanghai Zhangjiang Biotechnology (ZJ-Bio)
  • Sirnaomics
  • Sorrento Biologics/Therapeutics
  • Spectrum Pharmaceuticals
  • Stada Arzneimittel
  • STC Biologics
  • Syd labs
  • Symphogen
  • Synthon Biopharmaceuticals
  • Taisho Pharmaceutical
  • Takeda Pharmaceutical Co
  • TG Therapeutics
  • Therapeutics Protein International (TPI)
  • Tillots Pharma
  • Torrent Pharma
  • TPG Biologics
  • Trimer Biotech
  • Triphase Accelerator
  • TSH Pharma
  • Tyrogenex
  • UCB
  • Unum Therapeutics
  • Vaccinex
  • Valeant Pharmaceuticals
  • Valor Biotherapeutics
  • Wuhan YZY Biopharma
  • Xbrane Biopharma
  • Xencor
  • YL Biologics
  • Yuhan
  • Zhejiang Huahai Pharmaceutical Co
  • Zhejiang Medicine
  • Zova Biotherapeutics
  • Zydus Cadila
  • Zymeworks
  • Zyngenia
Back to Top